Mean platelet volume as a fibrosis marker in patients with chronic hepatitis C

However, it should not be forgotten that MPV is not a specific marker for fibrosis, and the negative predictive rate seems more valuable to exclude a high fibrosis ratio in patients with CHC.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:We designed this study to evaluate the role of mean platelet volume (MPV) as a fibrosis marker in patients with chronic hepatitis C (CHC).

📊

Key Findings & Data:The control group comprised 33 age- and sex-matched healthy individuals.

💡

Conclusion & Impact:However, it should not be forgotten that MPV is not a specific marker for fibrosis, and the negative predictive rate seems more valuable to exclude a high fibrosis ratio in patients with CHC.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Key words: MPV · chronic hepatitis C · fibrosis

Abstract

We designed this study to evaluate the role of mean platelet volume (MPV) as a fibrosis marker in patients with chronic hepatitis C (CHC). Materials and methods: The study was designed at Kayseri Education and Research Hospital. Ninety-five patients with CHC were enrolled retrospectively into the study. The control group comprised 33 age- and sex-matched healthy individuals. Hepatitis C virus-RNA level, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, prothrombin time (PT), platelet count (PC), serum albumin, histological activity index (HAI), liver fibrosis score (LFS), and MPV were obtained from the patients' files and a computerized database. Results: Statistically significant differences in MPV and PC were seen in patients with CHC compared to healthy controls (MPV: 9.1 ± 1.31 fL vs. 8.58 ± 0.8 fL, P = 0.008; PC (×103/µL): 219.37 ± 74.31 vs. 258.52 ± 48.34, P = 0.001). In multivariate analysis, 4 variables remained as independent risk factors: AST (OR 1.11, 95% CI 1.02 to 1.21), ALT (OR 0.92, 95% CI 0.86 to 0.99), PT (OR 2.11, 95% CI 1.15 to 3.88), and MPV (OR 2.28, 95% CI 1.22 to 4.25). Cut-off values were calculated for diagnostic performance, and the cut-off value for MPV was 8.4 fL. Conclusion: We suggest that high MPV levels (especially those over 8.4 fL) may help to predict advanced fibrosis in patients with CHC. However, it should not be forgotten that MPV is not a specific marker for fibrosis, and the negative predictive rate seems more valuable to exclude a high fibrosis ratio in patients with CHC.

Özet

We designed this study to evaluate the role of mean platelet volume (MPV) as a fibrosis marker in patients with chronic hepatitis C (CHC). Materials and methods: The study was designed at Kayseri Education and Research Hospital. Ninety-five patients with CHC were enrolled retrospectively into the study. The control group comprised 33 age- and sex-matched healthy individuals. Hepatitis C virus-RNA level, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, prothrombin time (PT), platelet count (PC), serum albumin, histological activity index (HAI), liver fibrosis score (LFS), and MPV were obtained from the patients' files and a computerized database. Results: Statistically significant differences in MPV and PC were seen in patients with CHC compared to healthy controls (MPV: 9.1 ± 1.31 fL vs. 8.58 ± 0.8 fL, P = 0.008; PC (×103/µL): 219.37 ± 74.31 vs. 258.52 ± 48.34, P = 0.001). In multivariate analysis, 4 variables remained as independent risk factors: AST (OR 1.11, 95% CI 1.02 to 1.21), ALT (OR 0.92, 95% CI 0.86 to 0.99), PT (OR 2.11, 95% CI 1.15 to 3.88), and MPV (OR 2.28, 95% CI 1.22 to 4.25). Cut-off values were calculated for diagnostic performance, and the cut-off value for MPV was 8.4 fL. Conclusion: We suggest that high MPV levels (especially those over 8.4 fL) may help to predict advanced fibrosis in patients with CHC. However, it should not be forgotten that MPV is not a specific marker for fibrosis, and the negative predictive rate seems more valuable to exclude a high fibrosis ratio in patients with CHC.

Keywords

Key words: MPV chronic hepatitis C fibrosis

🔖

Cite This Article

POYRAZOĞLU, O. K., ZARARSIZ, G., YALÇIN, S., KARAMAN, A., TAŞDEMİR, E. A., KARAMAN, H., KAYMAN, T., KARAKÜKCÜ, Ç. (2022). Mean platelet volume as a fibrosis marker in patients with chronic hepatitis C. Turkish Journal of Medical Sciences, Cilt: 43 - Sayı: 1, 39–45. https://ajindex.com/articles/611123

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (11)

Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science 1989; 244: 359–62.
Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494–500. van der Poel CL, Reesink HW, Lelie PN, Leentvaar-Kuypers A, Choo QL, Kuo G et al. Anti-hepatitis C antibodies and non-A, non-B post-transfusion hepatitis in the Netherlands. Lancet 1989; 2: 297–8.
Öner S, Yapıcı G, Şaşmaz CT, Kurt AÖ, Buğdaycı R. Hepatitis B, hepatitis C, HIV, and VDRL seroprevalence of blood donors in Mersin, Turkey. Turk J Med Sci 2011; 41: 335–41.
Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995; 21: 639–44.
Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339–44.
Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010; 52: 1216–24. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35–46. Park Y, Schoene N, Harris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets 2002; 13: 301–6.
Bancroft AJ, Abel EW, Mclaren M, Belch JJ. Mean platelet volume is a useful parameter: a reproducible routine method using a modified Coulter thrombocytometer. Platelets 2000; 11: 379–87.
Giles H, Smith RE, Martin JF. Platelet glycoprotein IIb-IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest 1994; 24: 69–72.
Kiliçli-Camur N, Demirtunç R, Konuralp C, Eskiser A, Başaran Y. Could mean platelet volume be a predictive marker for acute myocardial infarction? Med Sci Monit 2005: 11: 387–92.
Pizzulli L, Yang A, Martin JF, Lüderitz B. Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain. Eur Heart J 1998: 19: 80–4.
Bath P, Algert C, Chapman N, Neal B; PROGRESS Collaborative Group. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 2004: 35: 622–